Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 19:15:1429709.
doi: 10.3389/fphar.2024.1429709. eCollection 2024.

Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis

Jinger Lin  1 , Min Luo  1 , Qianwei Zhuo  1 , Nuo Chen  1 , Haosong Zhang  1 , Yue Han  1
Affiliations

Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis

Jinger Lin et al. Front Pharmacol. .

Abstract

Background: Lebrikizumab, an IL-13 immunomodulator, has shown recommendable effectiveness and safety in clinical studies for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents and adults.

Objective: To evaluate the efficacy and safety of lebrikizumab in the treatment of moderate-to-severe AD through a meta-analysis.

Methods: PubMed, Embase, Web of Science, Medline, and ClinicalTrials.gov databases were searched up to 8 August 2023. Randomized clinical trials of lebrikizumab treatment for moderate-to-severe AD were included by screening titles, abstracts, and papers.

Results: Five studies involving 1,551 patients with AD were identified. Pooled analysis revealed significant improvements in the Eczema Area and Severity Index (EASI) score (SMD = -0.527; 95% CI = [-0.617, -0.436]), Investigator's Global Assessment (IGA) score (RR = 2.122; 95% CI = [1.803, 2.496]), Body Surface Area (BSA) score (SMD = -0.608; 95% CI = [-1.099, -0.118]), SCORing Atopic Dermatitis (SCORAD) score (SMD = -0.441; 95% CI = [-0.633, -0.250]). Moreover, Pruritus Numeric Rating Scale (P-NRS) score, Patient-oriented Eczema Measure (POEM) scores, Sleep-loss score and Dermatology Life Quality Index (DLQI) scores showed similar results. Adverse events (AEs) (RR = 0.984; 95% CI = [0.907, 1.068]) for lebrikizumab showed no statistically significant difference compared to placebo, with similar results for serious adverse events (SAEs) (RR = 0.748; 95% CI = [0.410, 1.364]).

Conclusion: This meta-analysis reveals that lebrikizumab has higher efficacy and safety in the treatment of moderate-to-severe AD, with the 250 mg Q2W dosage regimen appearing to be more advantageous.

Keywords: atopic dermatitis; efficacy; lebrikizumab; meta-analysis; safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
PRISMA flow diagram of study selection.
FIGURE 2
FIGURE 2
Risk of bias summary for each included RCT. (A) Bias risk assessment according to the Cochrane Handbook of Systematic Reviews 5.1.0. (B) Funnel plot to detect publication bias. RCTs, randomized control trials.
FIGURE 3
FIGURE 3
Forest plots of the efficacy of lebrikizumab treatment in the 5 RCTs: (A) Eczema Area and Severity Index (EASI) score; (B) Investigator’s Global Assessment (IGA) score; (C) Body Surface Area (BSA) score; (D) SCORing Atopic Dermatitis (SCORAD) score. Horizontal lines represent 95% CIs of the RR estimates. Green dots represent the SMD, blue dots represent RR, and diamonds represent the meta-analysis summary effect estimate. RCTs, randomized control trials; RR, relative risk; SMD, standardized mean difference.
FIGURE 4
FIGURE 4
Forest plots of the efficacy of lebrikizumab treatment in the five RCTs: (A) Pruritus Numerical Rating Scale (P-NRS) score; (B) Pruritus Numerical Rating Scale (P-VAS) score; (C) Patient-Oriented Eczema Measure (POEM) score; (D) Sleep-loss score; (E) Dermatology Life Quality Index (DLQI) score. Horizontal lines represent 95% CIs of the RR estimates. Green dots represent the SMD, and diamonds represent the meta-analysis summary effect estimate. RCTs, randomized control trials; RR, relative risk; SMD, standardized mean difference.
FIGURE 5
FIGURE 5
Forest plots of rate of AEs and SAEs in the five RCTs. Blue dots represent the RR, and diamonds represent the meta-analysis summary effect estimate. RCTs, randomized control trials; RR, relative risk; AEs, adverse events; SAEs, serious adverse events.
FIGURE 6
FIGURE 6
Galbraith plot for each included RCT. RCTs, randomized control trials.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. A B., E G. Y., C L., S K., J S., S I., et al. (2024). Cendakimab in patients with moderate to severe atopic dermatitis: a randomized clinical trial. JAMA dermatol. 160 (8), 856–864. 10.1001/jamadermatol.2024.2131 - DOI - PMC - PubMed
    1. Ali F., Vyas J., Finlay A. Y. (2020). Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm. Venereol. 100 (12), adv00161. 10.2340/00015555-3511 - DOI - PMC - PubMed
    1. Arents B. W. M., van Zuuren E. J., Hughes O., Fedorowicz Z., Flohr C. (2023). The future is now: the global atopic dermatitis atlas (GADA). Br. J. Dermatol ljad286. 10.1093/bjd/ljad286 - DOI - PubMed
    1. Bashrahil B., Alzahrani Z., Samarkandy S., Aman A., Jfri A. (2022). The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. Front. Med. 9, 1091271. 10.3389/fmed.2022.1091271 - DOI - PMC - PubMed
    1. Bawany F., Northcott C. A., Beck L. A., Pigeon W. R. (2021). Sleep disturbances and atopic dermatitis: relationships, methods for assessment, and therapies. J. Allergy Clin. Immunol. Pract. 9 (4), 1488–1500. 10.1016/j.jaip.2020.12.007 - DOI - PMC - PubMed

Publication types

LinkOut - more resources